Shares in Dexcom (NSDQ:DXCM) dropped nearly 6.8% this morning following comments by a company executive that the company is facing “headwinds” that could hamper third-quarter results, according to a report by SeekingAlpha. EVP and CFO Quentin Blakford told attendees at Morgan Stanley’s Healthcare Conference in New York that comparisons to Q3 2018 results could be difficult, and that […]
Dexcom claims win in patent war with AgaMatrix unit Waveform Technologies
Dexcom Inc. (NSDQ:DXCM) last week claimed a win along one front of its patent war with AgaMatrix subsidiary WaveForm Technologies, when an Oregon federal court dismissed a lawsuit alleging that its continuous glucose monitors infringe WaveForm patents. Wilsonville, Ore.-based WaveForm sued Dexcom in March 2016, alleging infringement of a trio of patents covering a compound […]
Dexcom posts Street-beating Q2 earnings
Dexcom (NSDQ:DXCM) posted second-quarter results this evening that beat the consensus forecast on Wall Street, and raised its outlook for the rest of the year. The San Diego–based continuous glucose monitoring (CGM) technology company reported a loss of $10.5 million, or $0.12 per share, on sales of $336.4 million for the three months ended June 30. […]
Inside Insulet’s pivotal year with CEO Shacey Petrovic
It’s been a busy year at Insulet (NSDQ:PODD). The diabetes tech company welcomed a new CEO, launched its first new product in six years and officially opened its $200 million global headquarters – all in the first half of 2019. That’s all the result of years of rapid growth for Insulet, chief executive Shacey Petrovic said in […]
Dexcom plans Apple Watch CGM launch
Dexcom Inc. (NSDQ:DXCM) is reportedly launching upgrades for its G6 diabetes system and plans to launch its direct-to-Apple Watch version over the next year. The Apple and Dexcom collaboration would allow diabetes patients to track glucose through the Apple Watch, a consumer wearable, according to CNBC. Get the full story on our sister site, Drug Delivery Business […]
Beta Bionics touts results of bionic pancreas system study
Beta Bionics’ iLet bionic pancreas system significantly increased the percentage of time that adults with Type 1 diabetes spent with glucose levels between 70–180 mg/dl when compared to usual care therapy, according to a new study. The study’s results also suggest that the iLet, using either the Senseonics (NYSE:SENS)Eversense continuous glucose monitoring system (CGM) or […]
Dexcom, Companion Medical will share glucose, insulin data
DexCom (NSDQ:DXCM) and Companion Medical have announced a collaboration to enable a direct exchange of continuous glucose monitoring (CGM) data from Dexcom with insulin data from InPen into both companies’ software applications. Companion made a partnership deal with Glooko this week to integrate data from its InPen smart insulin injection pen into Glooko’s diabetes data management system and mobile […]
Dexcom shares steady after posting Street-beating Q1 earnings
Shares in Dexcom (NSDQ:DXCM) are steady in after-hours trading today after the diabetes-focused device maker posted first quarter 2019 earnings that topped loss-per-share and sales expectations. The San Diego-based company posted losses of $26.9 million, or 30¢ per share, on sales of $280.5 million for the three months ended March 31, seeing losses grow 11.2% while […]
Glooko, Novo Nordisk team up for connected insulin pens
Glooko announced this month that it’s teaming up to connect Novo Nordisk‘s (NYSE:NVO) insulin pens with the company’s diasend diabetes management solution. Novo Nordisk plans to launch its connected insulin pens, the NovoPen 6 and NovoPen Echo Plus, in early 2019. Any provider using diasend and any person using the diasend mobile app will be able to sync […]
Dexcom wins Health Canada nod for G6 CGM
Dexcom (NSDQ:DXCM) said last week that it won Health Canada approval for its G6 continuous glucose monitoring system for people with diabetes ages two and up. The company plans to kick off the G6 commercial launch later this year. Get the full story at our sister site, Drug Delivery Business News.
Dexcom beats The Street with Q4, FY18 results
Dexcom (NSDQ:DXCM) topped expectations on Wall Street this week with its fourth quarter and full-year financial results. The San Diego, Calif.-based company posted a net loss of -$179.7 million, or -$2.03 per share, on sales of $338 million for the 3 months ended Dec. 31, for sales growth of 52.9% compared with the same period last […]
- 1
- 2
- 3
- …
- 13
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
YouTube